Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)
Close on Nov 17, 2026Market cap $3.73BP/E –Yield –
Tango Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Tango Therapeutics's enterprise value was $3.33B on Nov 11, 2026, against $1.06B a year earlier. Over the last 5 years it ranged from -$110.31M to $4.13B, with a median of $414.16M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.33B | +298.8% |
| 2025 | Dec 31, 2025 | $835.68M | +2063.1% |
| 2024 | Dec 31, 2024 | $38.63M | -94.0% |
| 2023 | Dec 29, 2023 | $648.41M | +164.4% |
| 2022 | Dec 30, 2022 | $245.19M | -46.0% |
| 2021 | Dec 31, 2021 | $453.93M | +184.4% |
| 2020 | Dec 31, 2020 | $159.58M | – |
See a number that looks wrong?